Edition:
United Kingdom

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

60.20USD
13 Dec 2017
Change (% chg)

$1.25 (+2.12%)
Prev Close
$58.95
Open
$58.75
Day's High
$60.50
Day's Low
$58.75
Volume
66,246
Avg. Vol
172,351
52-wk High
$66.55
52-wk Low
$35.50

Latest Key Developments (Source: Significant Developments)

Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trial
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals initiates netarsudil ophthalmic solution Phase 2 clinical trial designed to meet requirements of regulatory filing in Japan.Aerie Pharmaceuticals Inc - ‍for Rhopressa, U.S. FDA PDUFA goal date of February 28, 2018​.  Full Article

Aerie Pharmaceuticals Q3 loss per share $0.89
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 adjusted loss per share $0.71.Q3 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.Q3 gaap loss per share $0.89.Aerie Pharmaceuticals Inc - ‍as of september 30, 2017, Aerie had $282.2 million in cash, cash equivalents and investments​.  Full Article

Aerie Pharmaceuticals says ‍FDA committee to review NDA for Rhopressa
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals Inc - ‍FDA advisory committee to review new drug application for Rhopressa (netarsudil ophthalmic solution) 0.02 pct​.  Full Article

Aerie Pharmaceuticals enters into controlled equity offering sales agreement with Cantor Fitzgerald
Thursday, 25 May 2017 

May 25 (Reuters) - Aerie Pharmaceuticals Inc :Aerie Pharmaceuticals - on May 25, co entered into controlled equity offering sales agreement with Cantor Fitzgerald & Co. - SEC filing.Aerie Pharmaceuticals - under agreement co may offer and sell shares of common stock, having an aggregate offering price of up to $50 million.  Full Article

Aerie Pharma's Roclatan succeeds in second late-stage study
Wednesday, 24 May 2017 

May 24 (Reuters) - Aerie Pharmaceuticals Inc :Aerie pharmaceuticals reports positive roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% phase 3 topline efficacy results.Aerie pharmaceuticals inc - ‍roclatan™ successfully achieves primary efficacy endpoint in mercury 2 study​.Aerie pharmaceuticals inc - ‍if mercury 1 12-month safety results are also successful, we expect to submit roclatan nda in first half of 2018​.  Full Article

Aerie pharmaceuticals updates full-year 2016 cash burn guidance
Thursday, 22 Sep 2016 

Aerie Pharmaceuticals Inc : Expects cash and cash equivalents to total approximately $230 million as of December 31, 2016 . Updated full-year 2016 cash burn guidance to approximately $85 million, an increase from previous guidance of $75 million .Updated guidance reflects initiatives like start-up of clinical trials in Japan, construction of manufacturing plant in Ireland.  Full Article

Aerie Pharmaceuticals submits NDA to U.S. Food and drug administration for Rhopressa
Tuesday, 6 Sep 2016 

Aerie Pharmaceuticals Inc :Submits new drug application to U.S. Food and Drug Administration for Rhopressa (netarsudil ophthalmic solution) 0.02 percent.  Full Article

Aerie pharmaceuticals reports Q2 2016 financial results and provides business update
Wednesday, 3 Aug 2016 

Aerie Pharmaceuticals Inc : Aerie Pharmaceuticals reports second quarter 2016 financial results and provides business update . Q2 GAAP loss per share $0.87 . Q2 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S . Q2 adjusted loss per share $0.72 .Aerie Pharmaceuticals Inc says remains on track to file its NDA for Rhopressa(TM)(Netarsudil Ophthalmic Solution) 0.02% in Q3 of 2016.  Full Article

Aerie Pharma completes enrollment of phase 3 clinical trial of eye drug Rhopressa
Thursday, 16 Jun 2016 

Aerie Pharmaceuticals Inc : Trial on track for topline 90-day interim efficacy readout in q4 2016 . Rocket 4 designed for eu filing; not required for us nda filing . Expect to file for european approval of rhopressa in second half of 2017 .Aerie pharmaceuticals completes enrollment of rocket 4 phase 3 clinical trial of rhopressatm (netarsudil ophthalmic solution) 0.02%.  Full Article

Aerie Pharmaceuticals, Inc reports positive rhopressatm qd interim safety results for rocket 2
Wednesday, 17 Feb 2016 

Aerie Pharmaceuticals, Inc:Reports positive rhopressatm qd (netarsudil ophthalmic solution) 0.02% 12 month interim safety results for rocket 2.Says preliminary cash burn for full-year 2015 is consistent with earlier guidance of approximately $60 million.  Full Article

BRIEF-Aerie Pharmaceuticals Appoints Heather Johnson As Regional Sales Director For Northeast Region

* AERIE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF HEATHER JOHNSON AS REGIONAL SALES DIRECTOR FOR THE NORTHEAST REGION Source text for Eikon: Further company coverage: